Literature DB >> 3262874

Neonatal administration of prolactin antiserum alters the developmental pattern of T- and B-lymphocytes in the thymus and spleen of BALB/c female mice.

D H Russell1, K T Mills, F J Talamantes, H A Bern.   

Abstract

We have evaluated the effect of neonatal administration of mouse prolactin (PRL) antiserum on the developmental expression of T- and B-lymphocytes in the thymus and spleen of female BALB/c mice. Newborn female mice were injected subcutaneously with a 50-microliters aliquot of PRL antiserum or normal rabbit serum on days 1, 2, and 3. On neonatal day 5, the PRL antiserum-treated group had a significantly (P less than 0.05) increased population of cells in the thymus and the spleen that were positive for Thy-1.2 and for L3T4. Increases in Thy-1.2- and L3T4-positive cells in the thymus were detectable also on days 8 and 14 in mice that received the PRL antiserum and in mice injected with bromocriptine, a dopamine agonist that inhibits PRL release from the anterior pituitary. On neonatal days 21, 28, and 32, there were no significant differences in the percentage of cells positive for Thy-1.2, Ly-2 (formerly Lyt-2), or L3T4 antigens in the thymus. However, there were significant increases in the percentage of Thy-1.2- and L3T4-positive spleen cells in the bromocriptine-treated group at all times monitored and in the PRL antiserum-treated group except on day 14. In addition, the percentage of splenocytes that were positive for IgG was significantly increased in the PRL antiserum-treatment group on days 8-28, although not on neonatal day 32. Of tissues known to contain PRL receptors, neonatal administration of PRL antiserum or bromocriptine resulted in a significant alteration in the wet weight of spleen and liver, with no significant effect in thymus, heart, and kidney. Pituitary implants also resulted in a significant increase in both concanavalin A- and lipopolysaccharide-stimulated thymidine incorporation into murine splenic lymphocytes prepared from 45-day-old female mice. These data extend the role of PRL as an immunomodulator of adult lymphocyte function to a role in the developmental expression of T- and B-lymphocyte populations in the thymus and spleen of mice.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3262874      PMCID: PMC282195          DOI: 10.1073/pnas.85.19.7404

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  Reduced number of natural killer cells in patients with pathological hyperprolactinemia.

Authors:  R Gerli; P Rambotti; I Nicoletti; S Orlandi; G Migliorati; C Riccardi
Journal:  Clin Exp Immunol       Date:  1986-05       Impact factor: 4.330

2.  Didemnin B: a new immunosuppressive cyclic peptide with potent activity in vitro and in vivo.

Authors:  D W Montgomery; C F Zukoski
Journal:  Transplantation       Date:  1985-07       Impact factor: 4.939

3.  Effect of exogenous prolactin on immunity in chickens.

Authors:  J Sotowska-Brochocka; D Rosołowska-Huszcz; K Skwarło-Sońta; A Gajewska
Journal:  Res Vet Sci       Date:  1984-07       Impact factor: 2.534

4.  Prolactin receptors on human T and B lymphocytes: antagonism of prolactin binding by cyclosporine.

Authors:  D H Russell; R Kibler; L Matrisian; D F Larson; B Poulos; B E Magun
Journal:  J Immunol       Date:  1985-05       Impact factor: 5.422

5.  Regulation of immunity in rats by lactogenic and growth hormones.

Authors:  E Nagy; I Berczi; H G Friesen
Journal:  Acta Endocrinol (Copenh)       Date:  1983-03

6.  Cyclosporine inhibits prolactin induction of ornithine decarboxylase in rat tissues.

Authors:  D H Russell; D F Larson; S B Cardon; J G Copeland
Journal:  Mol Cell Endocrinol       Date:  1984-05       Impact factor: 4.102

7.  Interleukin-2 production in the neonatal mouse.

Authors:  B F Argyris; M DeStefano; K W Zamkoff
Journal:  Transplantation       Date:  1985-09       Impact factor: 4.939

8.  Prolactin as a modulator of lymphocyte responsiveness provides a possible mechanism of action for cyclosporine.

Authors:  P C Hiestand; P Mekler; R Nordmann; A Grieder; C Permmongkol
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

9.  Prolactin receptors on human lymphocytes and their modulation by cyclosporine.

Authors:  D H Russell; L Matrisian; R Kibler; D F Larson; B Poulos; B E Magun
Journal:  Biochem Biophys Res Commun       Date:  1984-06-29       Impact factor: 3.575

10.  Immunomodulation by bromocriptine.

Authors:  E Nagy; I Berczi; G E Wren; S L Asa; K Kovacs
Journal:  Immunopharmacology       Date:  1983-10
View more
  6 in total

Review 1.  The role of prolactin in the pathogenesis of autoimmune disease.

Authors:  Istvan Berczi
Journal:  Endocr Pathol       Date:  1993-12       Impact factor: 3.943

Review 2.  Milk-borne prolactin and neonatal development.

Authors:  L A Ellis; A M Mastro; M F Picciano
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-07       Impact factor: 2.673

3.  50 kD prolactin binding protein in schizophrenics on neuroleptic medication.

Authors:  A M Walker; C A Peabody; T W Ho; M D Warner
Journal:  J Psychiatry Neurosci       Date:  1992-06       Impact factor: 6.186

4.  Depriving neonatal rats of milk from early lactation has long-term consequences on mammotrope development.

Authors:  K D Nusser; S Frawley
Journal:  Endocrine       Date:  1997-12       Impact factor: 3.633

5.  Prolactin increases CD4/CD8 cell ratio in thymus-grafted congenitally athymic nude mice.

Authors:  G O Gaufo; M C Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

6.  Suppression of B lymphopoiesis during normal pregnancy.

Authors:  K L Medina; G Smithson; P W Kincade
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.